Celadon’s Medicinal Cannabis Facility Awarded GMP Registration by MHRA
Medicinal cannabis manufacturer Celadon Pharmaceuticals has announced that its facility in the Midlands, UK has now received good manufacturing process (GMP) registration from the Medicines and Healthcare products Regulatory Agency (MHRA), the authority for pharma manufacturing in the UK.
GMP is a globally recognised standard of quality in the manufacture of pharmaceutical products. The certification is the first step for the company start production of their cannabis-based product for use in humans, including clinical trials.
Celadon currently only has the licence to grow the cannabis plant for test batches of their product. They have now requested an update to their current Home Office licence to begin commercialisation of their product.
- Leveraging In-Silico Tools for Optimised Process Development
- CROs, Strategy, and Sustainable Testing: Navigating Formulation Development for Biologics
"Whilst there is no guarantee that the Home Office will update the current licence, nor any timeframe for this, the directors are confident that the licence will be updated in due course," the company said in a statement.
Celadon’s GMP facility includes a closed-loop hydroponic cultivation system to grow the psychoactive shrub. It also contains a laboratory which works on the company’s product: tetrahydrocannabinol (THC) oil, which they extract from the cannabis plant.
THC is the compound responsible for the euphoric ‘high’ of cannabis, but also is said to have therapeutic properties for people suffering from difficulties including chronic pain, epilepsy, and multiple sclerosis.
Medicinal cannabis is a relatively new enterprise for the UK, with prescriptions for the drug only being allowed to be issued by specialist doctors since 2018.
James Short, Celadon’s CEO, said: “With the receipt of GMP registration, Celadon has joined a very select group of cannabis-focused pharmaceutical companies globally. This is a tremendous milestone for the company given the significant capital and regulatory requirements in this sector.”
RTTNews further reported that Celadon had seen an 8 percent share increase on the London Stock Exchange after the news of their certification.
Get your weekly dose of industry news?here?and keep up to date with the latest?‘Industry Spotlight’ posts.?For other Formulation content, please visit the?Formulation Content Portal.
